Diversity in antibody-based approaches to non-Hodgkin lymphoma.
about
From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignanciesA phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseTargeting castration-resistant prostate cancer with monoclonal antibodies and constructs.A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.
P2860
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@en
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@nl
type
label
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@en
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@nl
prefLabel
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@en
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
@en
P2093
Anton Hagenbeek
Christian Gisselbrecht
Franck Morschhauser
Ola Linden
P2860
P356
10.3109/10428194.2010.500047
P478
51 Suppl 1
P577
2010-08-01T00:00:00Z